Views & Analysis | Perspectives on pharma industry issues

R&D

Gravity is an experimental variable pharma has rarely been a...

Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.

Market Access

Biotech's next growth cycle: Renewed confidence comes with c...

Renewed confidence across biopharma is welcome and long overdue after a prolonged period of constraint. But confidence alone is not enough.

Oncology

The future of oncology is adaptive: What ESMO 2026 revealed ...

Across tumours, three developments repeatedly surfaced throughout the congress, each reflecting a notable transition in how cancer is being managed.

Market Access

Sponsored

Solution Spotlight: Acumetis Model Builder

Acumetis Model Builder is a web-based platform that generates complete, formula-linked Excel cost-effectiveness and budget impact models in minutes.

Articles

Top ten innovators in pharma: Dennis Urbaniak

We interview Dennis Urbaniak, nominated as top pharma innovator for being the mind and the force behind Sanofi’s innovative approach to engaging in social media. We asked you to nominate those who you considered to be a top innovator in pharma. We were delighted with your responses and....

Articles

Rare disease insight: interview with Timothy Coté

As our rare disease focus month continues, we interview Dr Timothy Coté, former Director of FDA’s Office of Orphan Products Development, on the Orphan Drug Act and the impact it has had on this previously neglected area. There are approximately 7,000 rare diseases, 200 of which have become treatable attributed, in no small part to the Orphan Drug…

Articles

Humanized FcRn Mice: promising tools for evaluating the phar...

Ray Lambert discusses humanized FcRn mice and their role in evaluating the pharmacokinetics of mAbs. Due to their extraordinary specificity and pharmacokinetic (PK) behavior, human immunoglobulin gamma monoclonal antibodies...

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.

Digital